STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Clinical trials for STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a new drug combo shrink tough lung tumors?
Disease control OngoingThis study tests whether adding the drug veliparib to standard chemotherapy and radiation helps people with stage III lung cancer that can't be removed by surgery. About 53 adults took part to find the best dose and see if the combination slows cancer growth. The goal is to impro…
Matched conditions: STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 07:04 UTC
-
New radiation approach aims to boost tumor kill while sparing healthy tissue
Disease control OngoingThis study tests a new way to give radiation to people with stage II to III non-small cell lung cancer. The goal is to deliver a higher dose directly to the tumor while keeping the dose to nearby healthy organs at standard levels. About 146 participants will receive either photon…
Matched conditions: STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 06:50 UTC
-
New combo tackles Drug-Resistant lung cancer
Disease control OngoingThis early-stage trial tests a combination of two drugs, sapanisertib and osimertinib, in people with advanced EGFR-mutant non-small cell lung cancer that has worsened after previous treatment. The main goal is to find the safest dose and check for side effects. About 36 particip…
Matched conditions: STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 06:50 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests the safety and best dose of combining two drugs, ceritinib and everolimus, in people with advanced solid tumors or a specific type of lung cancer (ALK-positive NSCLC). The goal is to find the highest dose that is safe and to see if the combination can…
Matched conditions: STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced or inoperable solid tumors, including certain breast, lung, and pancreatic cancers. The goal is to see if the combo can shrink tumors or slow their growth by blocking enzymes that cancer …
Matched conditions: STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:04 UTC